These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20978876)

  • 1. Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.
    Ichikawa M; Hangaishi A; Nannya Y; Kurokawa M
    Int J Hematol; 2010 Nov; 92(4):673-4. PubMed ID: 20978876
    [No Abstract]   [Full Text] [Related]  

  • 2. Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
    Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Ronconi S; Visani G; Baccarani M
    Haematologica; 2003 Dec; 88(12):ECR37. PubMed ID: 14688010
    [No Abstract]   [Full Text] [Related]  

  • 3. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
    Stasi R
    Expert Opin Biol Ther; 2008 Apr; 8(4):527-40. PubMed ID: 18352855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemtuzumab ozogamicin: time to resurrect?
    Ravandi F; Estey EH; Appelbaum FR; Lo-Coco F; Schiffer CA; Larson RA; Burnett AK; Kantarjian HM
    J Clin Oncol; 2012 Nov; 30(32):3921-3. PubMed ID: 22987091
    [No Abstract]   [Full Text] [Related]  

  • 6. Gemtuzumab ozogamicin: is there room for salvage?
    Clarke WT; Marks PW
    Blood; 2010 Oct; 116(14):2618-9. PubMed ID: 20930085
    [No Abstract]   [Full Text] [Related]  

  • 7. Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia.
    El Kinge AR; Hatoum HA; Mahfouz RA; Otrock ZK; Jabbour E; Kantarjian H; Bazarbachi A
    Leuk Res; 2009 Apr; 33(4):565-6. PubMed ID: 18571231
    [No Abstract]   [Full Text] [Related]  

  • 8. Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study.
    Poloni A; Capelli D; Trappolini S; Costantini B; Montanari M; Gini G; Scortechini I; Mancini G; Discepoli G; Leoni P; Olivieri A
    Br J Haematol; 2010 Jul; 150(1):119-21. PubMed ID: 20377587
    [No Abstract]   [Full Text] [Related]  

  • 9. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
    Molnár I; Powell BL
    Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.
    Chevallier P; Prebet T; Pigneux A; Hunault M; Delaunay J; Perry F; Lode L; Richebourg S; Blanchet O; Vey N; Ifrah N; Milpied N; Blaise D; Harousseau JL; Mohty M
    Leukemia; 2010 Feb; 24(2):467-9. PubMed ID: 19847200
    [No Abstract]   [Full Text] [Related]  

  • 11. [Revision of treatment with gemtuzumab ozogamicin using 3 clinical case studies].
    Fernández Cañabate E; Longoni Merino M; Estany Raluy C; Pla Poblador R
    Farm Hosp; 2008; 32(6):360-2. PubMed ID: 19232223
    [No Abstract]   [Full Text] [Related]  

  • 12. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.
    Löwenberg B; Beck J; Graux C; van Putten W; Schouten HC; Verdonck LF; Ferrant A; Sonneveld P; Jongen-Lavrencic M; von Lilienfeld-Toal M; Biemond BJ; Vellenga E; Breems D; de Muijnck H; Schaafsma R; Verhoef G; Döhner H; Gratwohl A; Pabst T; Ossenkoppele GJ; Maertens J; ; ;
    Blood; 2010 Apr; 115(13):2586-91. PubMed ID: 20103782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensorimotor peripheral neuropathy in an elderly AML patient in complete remission while receiving gemtuzumab ozogamicin as maintenance therapy.
    Romani C; Murru R; Adamo F; Di Tucci A; Sabiu D; Casula P; Angelucci E
    Ann Hematol; 2006 Jun; 85(6):411-2. PubMed ID: 16538500
    [No Abstract]   [Full Text] [Related]  

  • 14. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
    Stadtmauer EA
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia.
    Ravandi F; Kantarjian H
    Nat Rev Clin Oncol; 2012 May; 9(6):310-1. PubMed ID: 22547217
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation.
    Tachibana T; Tanaka M; Takasaki H; Numata A; Fujisawa S; Maruta A; Harada H; Mori H; Ishigatsubo Y; Kanamori H
    Int J Hematol; 2011 Dec; 94(6):580-2. PubMed ID: 22135078
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
    Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
    Asano H; Yamamoto G; Hosoi M; Takahashi T; Hangaishi A; Kurokawa M
    Leuk Res; 2010 Jul; 34(7):e152-3. PubMed ID: 20061019
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting leukemia cells with gemtuzumab ozogamicin.
    Treish IM
    Cancer Pract; 2000; 8(5):254-7. PubMed ID: 11898239
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia.
    Unal S; Cakir M; Kuşkonmaz B; Cetin M; Tuncer AM
    Turk J Pediatr; 2009; 51(1):69-71. PubMed ID: 19378895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.